A
APS
vs
S
S&P TSX Composite Index (Canada)
Over the past 12 months, APS has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of +470% compared to the S&P TSX Composite Index (Canada)'s +29% growth.
Stocks Performance
APS vs S&P TSX Composite Index (Canada)
Performance Gap
APS vs S&P TSX Composite Index (Canada)
Performance By Year
APS vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Aptose Biosciences Inc
Glance View
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in North York, Ontario and currently employs 41 full-time employees. The firm has two clinical-stage investigational products for hematologic malignancies: luxeptinib and APTO-253. The luxeptinib is a mutation agnostic Bruton’s tyrosine kinase (BTK) kinase inhibitor, which is in a Phase I a/b trial in patients with refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies and is in a separate Phase I a/b trial in patients with refractory acute myeloid leukemia (AML). Its APTO-253 is the clinical stage agent that directly targets the Master Regulator of Cell Cycle Entry and Proliferative Metabolism (MYC) oncogene and suppresses its expression, which is in a Phase I a/b clinical trial for the treatment of patients with relapsed.
